Scarica l'app Stockscreener
1.57
3.68%
-0.06
Dopo l'orario di chiusura:
1.53
-0.04
-2.55%
Precedente Chiudi:
$1.63
Aprire:
$1.64
Volume 24 ore:
1.55M
Relative Volume:
0.56
Capitalizzazione di mercato:
$73.13M
Reddito:
-
Utile/perdita netta:
$-37.65M
Rapporto P/E:
-0.9401
EPS:
-1.67
Flusso di cassa netto:
$-24.14M
1 W Prestazione:
-12.78%
1M Prestazione:
-21.50%
6M Prestazione:
+85.23%
1 anno Prestazione:
-63.06%
Intervallo 1D:
$1.525
$1.70
Intervallo di 1 settimana:
$1.525
$1.88
Portata 52W:
$0.60
$4.45
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Nome
Reviva Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
(408) 501-8881
Indirizzo
10080 N WOLFE ROAD, CUPERTINO
Confronta RVPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
1.57 | 73.13M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-20 | Iniziato | ROTH MKM | Buy |
| 2023-06-08 | Iniziato | The Benchmark Company | Speculative Buy |
| 2022-01-24 | Iniziato | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India
Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks
Unusually active option classes on open February 12th - TipRanks
Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat
Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World
How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News
Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Reviva Pharmaceuticals to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Reviva CEO to Showcase CNS Pipeline at Major Healthcare Conference - StockTitan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decline in Short Interest - MarketBeat
Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com
Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan
Is Reviva Pharmaceuticals Holdings Inc (RVPH) positioned for future growth? - SETE News
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World
HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Unusual Options Activity - Benzinga
Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Given Buy Rating at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat
Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World
Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria
Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital - MarketBeat
Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy - MarketBeat
Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN
Maxim Group raises Reviva stock to Buy, sets new target - Investing.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated at Roth Mkm - MarketBeat
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit -January 07, 2025 at 08:02 am EST - Marketscreener.com
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - GlobeNewswire
Reviva Pharmaceuticals CEO to Present at Lytham Partners Healthcare Summit 2025 - StockTitan
Reviva Pharmaceuticals Holdings Inc Azioni (RVPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):